PATENT CLAIM ANALYSIS

Application Number: 15768175
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "255030"]

Abstract:
Derivatives of N,N-diethyl-N′-phenyl-piperazine, a silent agonist of the mammalian α7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.

Claim (Index 19):
The method of  claim 18 , wherein the nicotinic acetylcholine receptor positive allosteric modulator (PAM) is the type II PAM 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea (PNU-120596).

Metadata:
- Claim Count in Document: 17.0
- Percentile: 91.0
- Lexical Diversity: 1.54839
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12576934', '12338849', '12787937', '12841547', '13080071']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7762682808411966
- 35 USC 102 Novelty (BERT): 0.5149692909599712
- Combined Prediction Score: 0.750138381853074
- Mean Citation Score: 289.32073
- Max Citation Score: 301.93973
- Similarity Product: 227.0192557326245

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test